SAN JOSE, CA – December 11, 2025 – In a pivotal move poised to redefine the landscape of semiconductor design and cybersecurity, Arteris, Inc. (NASDAQ: APLS), a leading provider of system IP for accelerating chiplet and System-on-Chip (SoC) creation, today announced its definitive agreement to acquire Cycuity, Inc., a pioneer in semiconductor cybersecurity assurance. This [...]
Apellis Pharmaceuticals exemplifies the GARP strategy with strong commercial growth, recent profitability, and a valuation attractive relative to biotech peers.
Discover Apellis Pharmaceuticals (APLS), an affordable growth stock with strong revenue growth, fair valuation, and solid financial health for investors.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Apellis Pharmaceuticals (APLS) Q3 2025 earnings crushed estimates, driven by strong drug sales and a major partnership payment. The company achieved profitability and positive market reaction.
During the last three months, 12 analysts shared their evaluations of Apellis Pharmaceuticals (NASDAQ: APLS), revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
